Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children

References

• Razin S, Yogev D, Naot Y. Molecular biology and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev. 1998;62(4):1094–1156.
   PubMed Web of Science ®Google Scholar
• Razin S. Adherence of pathogenic mycoplasmas to host cells. Biosci Rep. 1999;19(5):367–372.
   PubMed Web of Science ®Google Scholar
• Waites KB, Xiao L, Liu Y, et al. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev. 2017;30(3):747–809.
   PubMed Web of Science ®Google Scholar
• Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev. 2004;17(4):697–728.
   PubMed Web of Science ®Google Scholar
• Korppi M, Heiskanen-Kosma T, Kleemola M. Incidence of community-acquired pneumonia in children caused by Mycoplasma pneumoniae: serological results of a prospective, population-based study in primary health care. Respirology. 2004;9(1):109–114.
   PubMed Web of Science ®Google Scholar
• Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):e25–e76.
   PubMed Web of Science ®Google Scholar
• Biondi E, McCulloh R, Alverson B, et al. Treatment of mycoplasma pneumonia: a systematic review. Pediatrics. 2014;133(6):1081–1090.
   PubMed Web of Science ®Google Scholar
• Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev. 2008;32(6):956–973.
   PubMed Web of Science ®Google Scholar
• Lind K, Benzon MW, Jensen JS, et al. A seroepidemiological study of Mycoplasma pneumoniae infections in Denmark over the 50-year period 1946–1995. Eur J Epidemiol. 1997;13(5):581–586.
   PubMed Web of Science ®Google Scholar
• Chanock RM, Cook MK, Fox HH, et al. Serologic evidence of infection with Eaton agent in lower respiratory illness in childhood. N Engl J Med. 1960;262:648–654.
   PubMed Web of Science ®Google Scholar
• Chanock RM, Hayflick L, Barile MF. Growth on artificial medium of an agent associated with atypical pneumonia and its identification as a PPLO. Proc Natl Acad Sci USA. 1962;48:41–49.
   PubMed Web of Science ®Google Scholar
• Ferwerda A, Moll HA, De Groot R. Respiratory tract infections by Mycoplasma pneumoniae in children: a review of diagnostic and therapeutic measures. Eur J Pediatr. 2001;160(8):483–491.
   PubMed Web of Science ®Google Scholar
• Kingston JR, Chanock RM, Mufson MA, et al. Eaton agent pneumonia. Jama. 1961;176:118–123.
   PubMed Web of Science ®Google Scholar
• Critchley IA, Jones ME, Heinze PD, et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect. 2002;8(4):214–221.
   PubMed Web of Science ®Google Scholar
• Gardiner SJ, Gavranich JB, Chang AB. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev. 2015;1:CD004875.
   PubMedGoogle Scholar
• Bébéar CM, Pereyre S. Mechanisms of drug resistance in Mycoplasma pneumoniae. Curr Drug Targets Infect Disord. 2005;5(3):263–271.
   PubMedGoogle Scholar
• Bébéar C, Pereyre S, Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol. 2011;6(4):423–431.
   PubMed Web of Science ®Google Scholar
• Pereyre S, Goret J, Bébéar C. Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Front Microbiol. 2016;7:974.
   PubMed Web of Science ®Google Scholar
• Lucier TS, Heitzman K, Liu SK, et al. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae. Antimicrob Agents Chemother. 1995;39(12):2770–2773.
   PubMed Web of Science ®Google Scholar
• Pereyre S, Guyot C, Renaudin H, et al. In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2004;48(2):460–465.
   PubMed Web of Science ®Google Scholar
• Stopler T, Gerichter CB, Branski D. Antibiotic-resistant mutants of Mycoplasma pneumoniae. Isr J Med Sci. 1980;16(3):169–173.
   PubMedGoogle Scholar
• Principi N, Esposito S. Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection. J Antimicrob Chemother. 2013;68(3):506–511.
   PubMed Web of Science ®Google Scholar
• Cao B, Zhao C-J, Yin Y-D, et al. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis. 2010;51(2):189–194.
   PubMed Web of Science ®Google Scholar
• Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother. 2010;16(2):78–86.
   PubMed Web of Science ®Google Scholar
• Rocha EP, Blanchard A. Genomic repeats, genome plasticity and the dynamics of Mycoplasma evolution. Nucleic Acids Res. 2002;30(9):2031–2042.
   PubMed Web of Science ®Google Scholar
• Göbel U, Butler GH, Stanbridge EJ. Comparative analysis of mycoplasma ribosomal RNA operons. Isr J Med Sci. 1984;20(9):762–764.
   PubMedGoogle Scholar
• Spuesens EB, Meyer Sauteur PM, Vink C, et al. Mycoplasma pneumoniae infections–does treatment help? J Infect. 2014;69 Suppl 1:S42–S46.
   PubMed Web of Science ®Google Scholar
• Chironna M, Sallustio A, Esposito S, et al. Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children. J Antimicrob Chemother. 2011;66(4):734–737.
   PubMed Web of Science ®Google Scholar
• Dumke R, Stolz S, Jacobs E, et al. Molecular characterization of macrolide resistance of a Mycoplasma pneumoniae strain that developed during therapy of a patient with pneumonia. Int J Infect Dis. 2014;29:197–199.
   PubMed Web of Science ®Google Scholar
• Hantz S, Garnier F, Peuchant O, et al. Multilocus variable-number tandem-repeat analysis-confirmed emergence of a macrolide resistance-associated mutation in Mycoplasma pneumoniae during macrolide therapy for interstitial pneumonia in an immunocompromised child. J Clin Microbiol. 2012;50(10):3402–3405.
   PubMed Web of Science ®Google Scholar
• Itagaki T, Suzuki Y, Seto J, et al. Two cases of macrolide resistance in Mycoplasma pneumoniae acquired during the treatment period. J Antimicrob Chemother. 2013;68(3):724–725.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Oishi T, Miyata I, et al. Macrolide-resistant Mycoplasma pneumoniae infection, Japan, 2008–2015. Emerg Infect Dis. 2017;23(10):1703–1706.
   PubMed Web of Science ®Google Scholar
• Uehara S, Sunakawa K, Eguchi H, et al. Japanese guidelines for the management of respiratory infectious diseases in children 2007 with focus on pneumonia. Pediatr Int. 2011;53(2):264–276.
   PubMed Web of Science ®Google Scholar
• Pereyre S, Charron A, Renaudin H, et al. First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years. J Clin Microbiol. 2007;45(11):3534–3539.
   PubMed Web of Science ®Google Scholar
• Matsuoka M, Narita M, Okazaki N, et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother. 2004;48(12):4624–4630.
   PubMed Web of Science ®Google Scholar
• Stopler T, Branski D. Resistance of Mycoplasma pneumoniae to macrolides, lincomycin and streptogramin B. J Antimicrob Chemother. 1986;18(3):359–364.
   PubMed Web of Science ®Google Scholar
• Niitu Y, Hasegawa S, Suetake T, et al. Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics. J Pediatr. 1970;76(3):438–443.
   PubMedGoogle Scholar
• Okazaki N, Ohya H, Sasaki T. Mycoplasma pneumoniae isolated from patients with respiratory infection in Kanagawa Prefecture in 1976–2006: emergence of macrolide-resistant strains. Jpn J Infect Dis. 2007;60(5):325–326.
   PubMed Web of Science ®Google Scholar
• Morozumi M, Iwata S, Hasegawa K, et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2008;52(1):348–350.
   PubMed Web of Science ®Google Scholar
• Kawai Y, Miyashita N, Kubo M, et al. Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients. Antimicrob Agents Chemother. 2013;57(8):4046–4049.
   PubMed Web of Science ®Google Scholar
• Xin D, Mi Z, Han X, et al. Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob Agents Chemother. 2009;53(5):2158–2159.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ye X, Zhang H, et al. Multiclonal origin of macrolide-resistant Mycoplasma pneumoniae isolates as determined by multilocus variable-number tandem-repeat analysis. J Clin Microbiol. 2012;50(8):2793–2795.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ye X, Zhang H, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother. 2009;53(5):2160–2162.
   PubMed Web of Science ®Google Scholar
• Liu X, Jiang Y, Chen X, et al. Drug resistance mechanisms of Mycoplasma pneumoniae to macrolide antibiotics. Biomed Res Int. 2014;2014:320801.
   PubMed Web of Science ®Google Scholar
• Hong KB, Choi EH, Lee HJ, et al. Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000–2011. Emerg Infect Dis. 2013;19(8):1281–1284.
   PubMed Web of Science ®Google Scholar
• Yoon IA, Hong KB, Lee HJ, et al. Radiologic findings as a determinant and no effect of macrolide resistance on clinical course of Mycoplasma pneumoniae pneumonia. BMC Infect Dis. 2017;17(1):402.
   PubMedGoogle Scholar
• Wu H-M, Wong K-S, Huang Y-C, et al. Macrolide-resistant Mycoplasma pneumoniae in children in Taiwan. J Infect Chemother. 2013;19(4):782–786.
   PubMed Web of Science ®Google Scholar
• Kogoj R, Mrvic T, Praprotnik M, et al. Prevalence, genotyping and macrolide resistance of Mycoplasma pneumoniae among isolates of patients with respiratory tract infections, Central Slovenia, 2006 to 2014. Euro Surveill. 2015;20(37).
   PubMedGoogle Scholar
• Uldum SA, Bangsborg JM, Gahrn-Hansen B, et al. Epidemic of Mycoplasma pneumoniae infection in Denmark, 2010 and 2011. Euro Surveill. 2012 Feb 2;17(5). pii: 20073.
   Google Scholar
• Dumke R, Von Baum H, Lück PC, et al. Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany. Clin Microbiol Infect. 2010;16(6):613–616.
   PubMed Web of Science ®Google Scholar
• Pereyre S, Touati A, Petitjean-Lecherbonnier J, et al. The increased incidence of Mycoplasma pneumoniae in France in 2011 was polyclonal, mainly involving M. pneumoniae type 1 strains. Clin Microbiol Infect. 2013;19(4):E212–E217.
   PubMed Web of Science ®Google Scholar
• Ferguson GD, Gadsby NJ, Henderson SS, et al. Clinical outcomes and macrolide resistance in Mycoplasma pneumoniae infection in Scotland, UK. J Med Microbiol. 2013;62(Pt 12):1876–1882.
   PubMedGoogle Scholar
• Cardinale F, Chironna M, Chinellato I, et al. Clinical relevance of Mycoplasma pneumoniae macrolide resistance in children. J Clin Microbiol. 2013;51(2):723–724.
   PubMed Web of Science ®Google Scholar
• Eshaghi A, Memari N, Tang P, et al. Macrolide-resistant Mycoplasma pneumoniae in humans, Ontario, Canada, 2010–2011. Emerg Infect Dis. 2013;19(9):1525-1527.
   PubMed Web of Science ®Google Scholar
• Diaz MH, Benitez AJ, Cross KE, et al. Molecular detection and characterization of Mycoplasma pneumoniae among patients hospitalized with community-acquired pneumonia in the United States. Open Forum Infect Dis. 2015;2(3):ofv106.
   PubMed Web of Science ®Google Scholar
• Zheng X, Lee S, Selvarangan R, et al. Macrolide-resistant Mycoplasma pneumoniae, United States. Emerg Infect Dis. 2015;21(8):1470–1472.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Yamazaki T, Narita M, et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2006;50(2):709–712.
   PubMed Web of Science ®Google Scholar
• Matsubara K, Morozumi M, Okada T, et al. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J Infect Chemother. 2009;15(6):380–383.
   PubMed Web of Science ®Google Scholar
• Kawai Y, Miyashita N, Kubo M, et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. Antimicrob Agents Chemother. 2013;57(5):2252–2258.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang Y, Sheng Y, et al. More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother. 2014;58(2):1034–1038.
   PubMed Web of Science ®Google Scholar
• Spuesens EB, Meijer A, Bierschenk D, et al. Macrolide resistance determination and molecular typing of Mycoplasma pneumoniae in respiratory specimens collected between 1997 and 2008 in The Netherlands. J Clin Microbiol. 2012;50(6):1999–2004.
   PubMed Web of Science ®Google Scholar
• Wolff BJ, Thacker WL, Schwartz SB, et al. Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob Agents Chemother. 2008;52(10):3542–3549.
   PubMed Web of Science ®Google Scholar
• Cheong KN, Chiu SS, Chan BW, et al. Severe macrolide-resistant Mycoplasma pneumoniae pneumonia associated with macrolide failure. J Microbiol Immunol Infect. 2016;49(1):127–130.
   PubMedGoogle Scholar
• Hsieh YC, Tsao KC, Huang CG, et al. Life-threatening pneumonia caused by macrolide-resistant Mycoplasma pneumoniae. Pediatr Infect Dis J. 2012;31(2):208–209.
   PubMed Web of Science ®Google Scholar
• Lung DC, Chan YH, Kwong L, et al. Severe community-acquired pneumonia caused by macrolide-resistant Mycoplasma pneumoniae in a 6-year-old boy. Hong Kong Med J. 2011;17(5):407–409.
   PubMedGoogle Scholar
• Narita M, Tanaka H. Cytokines involved in the severe manifestations of pulmonary diseases caused by Mycoplasma pneumoniae. Pediatr Pulmonol. 2007;42(4):397.
   PubMed Web of Science ®Google Scholar
• Matsuda K, Narita M, Sera N, et al. Gene and cytokine profile analysis of macrolide-resistant Mycoplasma pneumoniae infection in Fukuoka, Japan. BMC Infect Dis. 2013;13:591.
   PubMed Web of Science ®Google Scholar
• Zuckerman JM. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am. 2004;18(3):621–649, xi–.
   PubMed Web of Science ®Google Scholar
• Kawai Y, Miyashita N, Yamaguchi T, et al. Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients. Respirology. 2012;17(2):354–362.
   PubMedGoogle Scholar
• Okada T, Morozumi M, Tajima T, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis. 2012;55(12):1642–1649.
   PubMed Web of Science ®Google Scholar
• Bao F, Qu J-X, Liu Z-J, et al. [The clinical characteristics, treatment and outcome of macrolide-resistant Mycoplasma pneumoniae pneumonia in children]. Zhonghua Jie He He Hu Xi Za Zhi. 2013;36(10):756–761. Chinese.
   PubMedGoogle Scholar
• To KK, Chan K-H, Fung Y-F, et al. Azithromycin treatment failure in macrolide-resistant Mycoplasma pneumoniae pneumonia. Eur Respir J. 2010;36(4):969–971.
   PubMed Web of Science ®Google Scholar
• Carris NW, Pardo J, Montero J, et al. Minocycline as A substitute for doxycycline in targeted scenarios: a systematic review. Open Forum Infect Dis. 2015;2(4):ofv178.
   PubMedGoogle Scholar
• Cao B, Qu JX, Yin YD, et al. Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance. Clin Respir J. 2017;11(4):419–429.
   PubMed Web of Science ®Google Scholar
• Ishiguro N, Koseki N, Kaiho M, et al. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients. PLoS One. 2017;12(3):e0173635.
   PubMed Web of Science ®Google Scholar
• Lung DC, Yip EK, Lam DS, et al. Rapid defervescence after doxycycline treatment of macrolide-resistant Mycoplasma pneumoniae-associated community-acquired pneumonia in children. Pediatr Infect Dis J. 2013;32(12):1396–1399.
   PubMed Web of Science ®Google Scholar
• Morozumi M, Okada T, Tajima T, et al. Killing kinetics of minocycline, doxycycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae. Int J Antimicrob Agents. 2017;50(2):255–257.
   PubMed Web of Science ®Google Scholar
• Zhao F, Lv M, Tao X, et al. Antibiotic sensitivity of 40 Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant isolates from Beijing, China. Antimicrob Agents Chemother. 2012;56(2):1108–1109.
   PubMed Web of Science ®Google Scholar
• Miyashita N, Akaike H, Teranishi H, et al. Macrolide-resistant Mycoplasma pneumoniae pneumonia in adolescents and adults: clinical findings, drug susceptibility, and therapeutic efficacy. Antimicrob Agents Chemother. 2013;57(10):5181–5185.
   PubMed Web of Science ®Google Scholar
• Gruson D, Pereyre S, Renaudin H, et al. In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively. Antimicrob Agents Chemother. 2005;49(3):1190–1193.
   PubMed Web of Science ®Google Scholar
• Dégrange S, Renaudin H, Charron A, et al. Reduced susceptibility to tetracyclines is associated in vitro with the presence of 16S rRNA mutations in Mycoplasma hominis and Mycoplasma pneumoniae. J Antimicrob Chemother. 2008;61(6):1390–1392.
   PubMed Web of Science ®Google Scholar
• Couldwell DL, Tagg KA, Jeoffreys NJ, et al. Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance. Int J STD AIDS. 2013;24(10):822–828.
   PubMed Web of Science ®Google Scholar
• Sánchez AR, Rogers RS 3rd, Sheridan PJ. Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity. Int J Dermatol. 2004;43(10):709–715.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Givner LB. Should tetracycline be contraindicated for therapy of presumed Rocky Mountain spotted fever in children less than 9 years of age? Pediatrics. 1990;86(1):123–124.
   PubMed Web of Science ®Google Scholar
• Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27(9):1329–1342.
   PubMed Web of Science ®Google Scholar
• Bradley JS, Kauffman RE, Balis DA, et al. Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. Pediatrics. 2014;134(1):e146–e153.
   PubMed Web of Science ®Google Scholar
• Jackson MA, Schutze GE; Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones. Pediatrics. 2016;138(5):e20162706.
   Web of Science ®Google Scholar